BioNTech Capital Expenditures from 2010 to 2024

BNTX Stock  USD 107.08  4.94  4.84%   
BioNTech Capital Expenditures yearly trend continues to be fairly stable with very little volatility. Capital Expenditures is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioNTech Capital Expenditures regression line of annual values had r-squared of  0.53 and arithmetic mean of  176,659,400. View All Fundamentals
 
Capital Expenditures  
First Reported
2018-06-30
Previous Quarter
141.8 M
Current Value
83 M
Quarterly Volatility
57.9 M
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Capital Expenditures Growth Pattern

Below is the plot of the Capital Expenditures of BioNTech SE over the last few years. Capital Expenditures are funds used by BioNTech SE to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of BioNTech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is BioNTech's Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Capital Expenditures10 Years Trend
Slightly volatile
   Capital Expenditures   
       Timeline  

BioNTech Capital Expenditures Regression Statistics

Arithmetic Mean176,659,400
Geometric Mean102,689,942
Coefficient Of Variation133.41
Mean Deviation170,612,907
Median57,742,000
Standard Deviation235,687,936
Sample Variance55548.8T
Range683M
R-Value0.73
Mean Square Error28365.5T
R-Squared0.53
Significance0
Slope38,216,075
Total Sum of Squares777683.2T

BioNTech Capital Expenditures History

2024740.8 M
2023705.5 M
2022363.3 M
2021154 M
202085.4 M
201971.1 M
201867.9 M

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Capital Expenditures, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Expenditures705.5 M740.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.